First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Kim-Son H Nguyen, Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USAAbstract: Epidermal growth factor–receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC)....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-09-01
|
| Series: | Biologics : Targets & Therapy |
| Online Access: | http://www.dovepress.com/first-line-treatment-of-egfr-mutant-non-small-cell-lung-cancer-the-rol-a11109 |